Date: 2014-09-30
Type of information: Milestone
Compound: three clinical candidates
Company: Evotec (Germany) Bayer (Germany)
Therapeutic area: Gynecological diseases - Women's health
Type agreement: R&D
development
commercialisation
Action mechanism:
Disease: endometriosis
Details: * On October 1, 2012, Evotec and Bayer Pharma have entered into a five-year, multi-target collaboration with the goal of developing three clinical candidates for the treatment of endometriosis. Both parties will contribute innovative drug targets and high quality technology infrastructures and will share the responsibility for early research and pre-clinical characterisation of potential clinical candidates in the disease area of endometriosis.
Financial terms: Bayer will be responsible for any subsequent clinical development and commercialisation. Evotec will receive €12 million as an upfront payment. Evotec may also receive additional pre-clinical, clinical and sales milestones of potentially up to €580 million, plus potential royalties of up to low double digit percent of net sales, depending on which party brought the compound to the collaboration and the successful development and approval of potential drug candidates.
Latest news: * On September 30, 2014, Evotec announced that its multi-target collaboration with Bayer has reached an important milestone for the transition of a molecule into pre-clinical development for the treatment of endometriosis. This milestone was achieved under the agreement between Evotec and Bayer signed in October 2012. The goal of this collaboration is to develop three clinical candidates within the five year alliance. Both parties contribute innovative drug targets and high-quality technology infrastructures and share the responsibility for early research and pre-clinical characterisation of potential clinical candidates in the disease area of endometriosis. Further financial details were not disclosed.
